Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Tagrisso
| Field | Information |
|---|---|
| Medication Name | Tagrisso |
| Generic Name | Osimertinib |
| Boxed/Label Warning | Interstitial Lung Disease/Pneumonitis, QT Interval Prolongation, Cardiomyopathy |
| Purpose | Treatment of certain types of non-small cell lung cancer (NSCLC) with specific EGFR mutations. |
| Mechanism of Action | Tyrosine kinase inhibitor (TKI) that targets epidermal growth factor receptor (EGFR) mutations. |
| Dosage Forms | Oral tablets |
| Available Strengths | 40 mg, 80 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Diarrhea, rash, dry skin, stomatitis, decreased appetite, fatigue. |
| Serious Side Effects | Interstitial lung disease (ILD), QT prolongation, cardiomyopathy, severe skin reactions (e.g., Stevens-Johnson Syndrome), ocular toxicities (e.g., keratitis), aplastic anemia. |
| Drug Interactions | Strong CYP3A inhibitors (e.g., ketoconazole), strong CYP3A inducers (e.g., rifampin), drugs that prolong the QT interval. |
| Important Notes | Regular monitoring for pulmonary symptoms, cardiac function, and skin reactions is crucial. Women of childbearing potential should use effective contraception. Consult with your healthcare provider about any new medications or supplements. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | Take the dose as soon as you remember unless it is less than 12 hours until your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double your dose to make up for the missed one. |
| Alternatives | Gefitinib (Iressa), Erlotinib (Tarceva), Afatinib (Gilotrif), Dacomitinib (Vizimpro) |
Tagrisso Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Gefitinib (Iressa) | EGFR tyrosine kinase inhibitor | First-generation EGFR TKI, used for EGFR-mutated NSCLC. |
| Erlotinib (Tarceva) | EGFR tyrosine kinase inhibitor | First-generation EGFR TKI, used for EGFR-mutated NSCLC. |
| Afatinib (Gilotrif) | EGFR tyrosine kinase inhibitor (irreversible) | Second-generation EGFR TKI, broad-spectrum EGFR inhibitor. |
| Dacomitinib (Vizimpro) | EGFR tyrosine kinase inhibitor (irreversible) | Second-generation EGFR TKI, can be more potent than some first-generation options. |
Tagrisso Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Diarrhea | Interstitial Lung Disease (ILD)/Pneumonitis |
| Rash | QT Interval Prolongation |
| Dry Skin | Cardiomyopathy |
| Stomatitis (mouth sores) | Severe Skin Reactions (e.g., Stevens-Johnson Syndrome) |
| Decreased Appetite | Ocular Toxicities (e.g., Keratitis) |
| Fatigue | Aplastic Anemia |
Tagrisso Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) | 80 mg once daily | 80 mg once daily | Take orally with or without food. Do not crush, chew, or split the tablet. |
